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Objective: Our earlier data showed that quantitative reverse tran-
scriptase–polymerase chain reaction can discriminate patients
with node-negative cancer who are at high risk for recurrence. The
objective of this study was to determine whether a new, more rapid
quantitative reverse transcriptase–polymerase chain reaction assay
could provide this information in a time frame suitable for intra-
operative decision making.
Methods: We studied formalin-fixed, archived lymph nodes from
30 patients with histologically determined node-negative
esophageal cancer with rapid quantitative reverse transcriptase–
polymerase chain reaction to measure expression of carcinoem-
bryonic antigen messenger RNA. We also performed rapid quan-
titative reverse transcriptase-polymerase chain reaction on 37
snap-frozen lymph nodes from 23 patients. Eleven of the 23
patients had benign esophageal disorders (negative control group). The other 12
had esophageal cancer, 6 with histologically determined positive lymph nodes and
6 with histologically determined negative lymph nodes.
Results: In the retrospective analysis of archival tissue from 30 patients with
esophageal cancer with histologically determined negative lymph nodes, rapid
quantitative reverse transcriptase–polymerase chain reaction predicted disease
recurrence with a sensitivity and a specificity of 90% and 80%, respectively, and
was comparable to conventional quantitative reverse transcriptase–polymerase
chain reaction. In the frozen-tissue analysis rapid quantitative reverse transcriptase-
polymerase chain reaction detected significantly higher levels of carcinoembryonic
antigen expression in all 12 of the histologically determined positive lymph nodes
than in the benign nodes. For 2 of these 12 nodes the intraoperative frozen-section
analysis had negative histologic results, and N1 status was determined only on final
pathologic examination. Rapid (intraoperative) quantitative reverse transcriptase–
polymerase chain reaction discriminated both nodes as positive. Among the 14 his-
tologically determined negative nodes, 1 of 3 nodes from 1 patient showed
increased carcinoembryonic antigen according to rapid quantitative reverse tran-
scriptase-polymerase chain reaction, and this patient had a clinical recurrence.
Conclusions: In our study we were able to rapidly discriminate patients with node
negative–esophageal cancer who had a high risk of recurrence. In frozen tissues
rapid quantitative reverse transcriptase-polymerase chain reaction correlated with
From the Departments of Surgery,a
Biostatistics,b and Pathology,c University of
Pittsburgh Medical Center, Pittsburgh, Pa.
Supported by National Institutes of Health
National Cancer Institute research grant
CA90665-01.
Read at the Eighty-first Annual Meeting of
The American Association for Thoracic
Surgery, San Diego, Calif, May 6-9, 2001.
Received for publication May 5, 2001; revi-
sions requested June 27, 2001; revisions
received Aug 16, 2001; accepted for publica-
tion Aug 30, 2001.
Address for reprints: Division of Thoracic
Surgery, Suite C-800 Presbyterian
University Hospital, 200 Lothrop St,
Pittsburgh, PA 15213.
J Thorac Cardiovasc Surg 2002;123:475-83
Copyright © 2002 by The American
Association for Thoracic Surgery.
0022-5223/2002 $35.00 + 0 12/6/119884
doi:10.1067/mtc.2002.119884
Rapid, quantitative reverse transcriptase–polymerase
chain reaction: Application to intraoperative molecular
detection of occult metastases in esophageal cancer
Siva Raja, BSa
James D. Luketich, MDa
Lori A. Kelly, BSa
William E. Gooding, MSb
Sydney D. Finkelstein, MDc
Tony E. Godfrey, PhDa
TX
ET
CS
P
G
TS
CH
D
G
TS
ED
IT
O
RI
A
L
Raja et al General Thoracic Surgery
Finkelstein, Raja, Gooding, Kelly, Godfrey, Luketich (left to right)
476 The Journal of Thoracic and Cardiovascular Surgery • March 2002
General Thoracic Surgery Raja et al
ED
ITO
RIA
L
CH
D
G
TS
G
TS
ET
CSP
TX
Surgical decisions in the treatment of eso-phageal cancer and other malignancies areoften based on intraoperative frozen-sectionanalysis of lymph nodes. The 5-year survivalfor patients with esophageal cancer remainspoor, at 5% to 10%, because of the presence of
advanced disease in many patients at initial presentation.1 If
local and regional lymph nodes are histologically negative,
there is a dramatic improvement in the 5-year survival.
Nevertheless, 30% to 50% of patients with histologically
node-negative disease have recurrence.2,3 This is most
likely because of the limitations of current staging tech-
niques in the detection of micrometastases. As a result,
other techniques, such as immunohistochemical examina-
tion or reverse transcriptase–polymerase chain reaction
(RT-PCR), have been used in attempts to detect histologi-
cally occult micrometastases.4-7
Studies on esophageal cancer,6 colon cancer,8
melanoma,9,10 and breast cancer11,12 have shown that RT-
PCR can detect histologically occult micrometastases and
may predict recurrence. These data have been criticized,
however, because of false-positive results in control sam-
ples and the subsequent low specificity and positive predic-
tive value of the RT-PCR assay. Recently we showed that
quantitative RT-PCR allows the distinction of background
or ectopic gene expression from true micrometastases and
can therefore avoid false-positive results and increase speci-
ficity in predicting disease recurrence.13 Our goal now is to
be able to provide the surgeon with this critical information
at a time when important surgical decisions are made, dur-
ing the operation.
In this study we report on the development and testing of
an extremely rapid quantitative RT-PCR assay that can be
carried out in less than 30 minutes. To validate the rapid
assay we compared it with standard quantitative RT-PCR
and correlated results with clinical outcomes among
patients with esophageal cancer.
Material and Methods
Patients
For the retrospective analysis we studied lymph nodes from 30
patients (Table 1) who underwent curative resection for histologi-
cally determined node-negative esophageal cancer. All operations
were performed in the Division of Thoracic Surgery at the
University of Pittsburgh Medical Center between 1991 and 1998.
Clinical follow-up was obtained from the medical records and was
confirmed for all patients as of August 2001. The median clinical
follow-up time for all patients was 36 months; that for the surviv-
ing patients was 49 months (range 28-91 months).
For the prospective analysis lymph node samples were
obtained from 12 patients undergoing either staging or resection
for esophageal cancer identified by the Section of Thoracic
Surgery at the University of Pittsburgh Medical Center from 1999
to 2000 (Table 2). Control nodes from patients without cancer
were obtained incidentally from patients undergoing abdominal
surgery for antireflux procedures. At the time of excision half of
each lymph node was frozen in liquid nitrogen for analysis, and
the remainder was sent for routine pathologic analysis. The
excised tissue was removed as part of the routine clinical course at
our institution, and no additional tissue was removed for any
purely research purpose. All tissues were collected as part of an
ongoing, institutional review board–approved Esophagus Cancer
Risk Registry protocol at the University of Pittsburgh.
Tissue and RNA Isolation
All tissues used in the retrospective study were formalin-fixed,
paraffin-embedded archival specimens obtained from the pathol-
ogy tissue banks. Hematoxylin and eosin–stained slides were also
retrieved for each tissue block and were examined to confirm the
original node-negative diagnosis. Tissue blocks were mounted on
a microtome, and 5 to 15 sections 5.0 µm thick were cut and
placed in 2.0 mL ribonuclease-free tubes. At the same time 2 sec-
tions 5.0 µm thick were cut (first and last sections) and mounted
on microscope slides for hematoxylin and eosin staining and also
immunohistochemical staining with antibodies against carcinoem-
bryonic antigen (CEA). RNA was isolated by means of previously
described methods14 and quantitated spectrophotometrically.
The fresh-frozen lymph node tissues were embedded in
Optimal Cutting Temperature compound and 10 to 15 sections 4.0
µm thick were cut. At the same time 2 sections 4.0 µm thick were
cut (first and last sections) and mounted on microscope slides for
hematoxylin and eosin staining. The remaining sections were
placed in 1.5 mL ribonuclease-free tubes with the lysis buffer from
the RNeasy Mini kit (QIAGEN Inc, Valencia, Calif). RNA was
extracted according to the manufacturer-recommended protocol
with the following modifications. Centrifugation times longer than
1 minute were reduced to 1 minute, and the RNA was reconstituted
in 60 µL RNA secure resuspension solution (Ambion Inc, Austin,
Tex). Although most of the samples were processed together, 5
final pathologic report for 11 of 12 patients. In the 1 discordant case, the quantita-
tive reverse transcriptase–polymerase chain reaction result was positive and may
have detected microscopically occult metastasis, because this patient did have dis-
ease recurrence. Rapid quantitative reverse transcriptase–polymerase chain reaction
was more sensitive than intraoperative frozen sections for detecting metastatic dis-
ease. These data suggest that rapid quantitative reverse transcriptase-polymerase
chain reaction may have a prognostic role and could guide intraoperative decisions.
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samples were processed individually to determine the median
extraction time per sample. The RNA yield and purity were deter-
mined spectrophotometrically for quality control purposes.
Quantitative RT-PCR
Quantitative RT-PCR was carried out with the 5´-nuclease
assay.15,16 Rapid quantitative RT-PCR was carried out on the
Cepheid Smart Cycler real-time DNA amplification and detection
system (Cepheid, Sunnyvale, Calif) as described here. Standard
quantitative RT-PCR was carried out on the Applied Biosystems
7700 Sequence Detection Instrument (TaqMan) with a single-tube
quantitative RT-PCR procedure as described previously else-
where.17
Rapid quantitative RT-PCR
Expression of the CEA gene was measured relative to that of the
endogenous control gene, the β-glucuronidase gene (GUSB) with
the comparative threshold cycle method described previously else-
where.14,18 All quantitative RT-PCR assays were carried out in
triplicate on 400 ng of total RNA. Both CEA and GUSB PCR
primers were designed and tested to avoid amplification of
genomic DNA. However, control reactions were still run with
RNA without reverse transcription (no transcription control) and
water (no template control) in place of complementary DNA as
PCR template. Together these control reactions ruled out the pos-
sibility that any signal was generated from either genomic DNA
contamination of the RNA or PCR product contamination of the
reagents. In addition, a calibrator RNA sample was amplified in
parallel on all runs to allow comparison of samples run at differ-
ent times14,19 and to determine reproducibility of the assay.
The final concentrations of the reaction components were as
follows: 1× PCR Platinum Taq buffer (Life Technologies, Inc,
Rockville, Md), 300-nmol/L concentrations of each deoxyribonu-
cleoside triphosphate, 4.5-mmol/L magnesium chloride, 0.8-U/µL
ribonuclease inhibitor, 1.25-U/µL Sensiscript reverse transcriptase
(QIAGEN), 0.06-U/µL Platinum Taq, 60-nmol/L reverse transcrip-
tion primer, 400-nmol/L concentrations of each PCR primer, 200-
nmol/L probe, and 400 ng total RNA. The total RNA input for the
fresh-tissue analysis was 5 µL of the sample. For the fixed-tissue
analysis 5 µL of an 80-ng/µL dilution of the RNA stock was used.
In the rapid assay the reverse transcription reaction was carried out
without the PCR primers or probe, then the tube was opened and
the primers and probe were added. This was necessary because a
standard single-step quantitative RT-PCR lacked the sensitivity to
detect rare messages.17 The oligonucleotide sequences used were
as follows: GUSB reverse transcription primer, 5´-TGG TTG TCT
TABLE 1. Clinical characteristics of the study population
Quantitative RT-PCR result
Characteristic Patients (n = 30) Negative (n = 17) Positive (n = 13)
Sex
Male 22 14 8
Female 8 3 5
Follow-up (mo)
Median 36 43.9 31.8
Range 5-90.5 5-90.5 6.3-75.6
Mean age at diagnosis (y) 68.3 68.4 68.2
Tumor type
Adenocarcinoma 26 16 10
Squamous cell 4 1 3
Stage*
0† 1 1 0
I 10 8 2
IIA 15 8 7
Median number of nodes examined 12.5 12 15
*Four patients who received chemotherapy had no tumor at operation.
†Patient had cancer on biopsy but not at resection.
TABLE 2. Tumor stage and histologic status for patients in
the rapid quantitative RT-PCR study on fresh-frozen lymph
nodes
Patient Stage Tumor type
12 IIA Adenocarcinoma
13 IIA Adenocarcinoma
14 I Adenocarcinoma
15 IIA Adenocarcinoma
16 IIA Adenocarcinoma
17 IIA Squamous cell
18 III Adenocarcinoma
19 III Adenocarcinoma
20 III Adenocarcinoma
21 III Adenocarcinoma
22 III Adenocarcinoma
23 III Adenocarcinoma
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CTG CCG A-3´; GUSB forward PCR primer, 5´-CTC ATT TGG
AAT TTT GCC GAT T-3´; GUSB reverse PCR primer, 5´-CCG
AGT GAA GAT CCC CTT TTT A-3´; GUSB probe 5´-VIC TGA
ACA GTC ACC GAC GAG AGT GCT GG-6-carboxyl-tetra-
methyl-rhodamine-3´ (VIC, Applied Biosystems, Foster City,
Calif); CEA reverse transcription primer, 5´-GTG AAG GCC ACA
GCA T-3´; CEA forward PCR primer, 5´-AGA CAA TCA CAG
TCT CTG CGG A-3´; CEA reverse PCR primer, 5´-ATC CTT GTC
CTC CAC GGG TT-3´; and CEA probe, 5´-6-carboxyfluorescein
CAA GCC CTC CAT CTC CAG CAA CAA CT-6-carboxy-
tetramethyl-rhodamine-3´. Rapid quantitative RT-PCR reactions
were carried out on the Cepheid Smart Cycler with the following
thermocycler conditions: 48°C hold for 5 minutes, 70°C for 60 sec-
onds (for the addition of the PCR primers and probe), 95°C hold for
30 seconds (for Platinum Taq activation), and 45 cycles of 95°C for
2 seconds and 64°C for 15 seconds. Data were analyzed by means
of Smart Cycler software (version 1.0) with the second derivative
method for determining the threshold. For the fixed-tissue analysis
a 30-minute reverse transcription reaction was required because of
the reduced sensitivity associated with the degradation inherent in
fixed-tissue RNA samples.14
Figure 1. Smart Cycler analysis of CEA expression in formalin-fixed lymph nodes from 30 patients with pathologically
determined node-negative esophageal cancer. Red bars represent patients with recurrence; blue bars represent
patients without recurrence. Lymph nodes with no detectable CEA expression were arbitrarily plotted at 0.02.
Dashed line indicates CEA expression cutoff value (0.183) most accurate for predicting disease recurrence.
TABLE 3. Rapid quantitative RT-PCR results on 30 patients
with pN0 esophageal cancer with a CEA expression cutoff
of 0.183
Quantitative Recurrence No recurrence
RT-PCR result (true positive) (true negative)
Positive 9 4
Negative 1 16
Sensitivity was 90% (9/10), and specificity was 80% (16/20).
Figure 2. Kaplan-Meier disease-free survival curve for 30 patients
with pN0 esophageal cancer restratified as node-positive
(dashed line) or node-negative (solid line) because of values
above or below cutoff value of 0.183 according to Smart Cycler
quantitative RT-PCR.
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Statistical Analysis
The predictive validity of rapid quantitative RT-PCR determina-
tion of CEA expression level was evaluated by proportionate haz-
ards regression for disease-free survival. Disease-free survival was
defined as the time from the operation to diagnosis of recurrent
esophageal cancer. Deaths from other causes and patients alive
without disease as of August 1, 2001, were censored. CEA expres-
sion was also used to classify patients as having either positive or
negative results of quantitative RT-PCR. The cutoff level for clas-
sification, as determined by receiver operating characteristic curve
analysis,20,21 was defined as the CEA expression level value that
produced the most accurate classification with disease recurrence
as the standard. Sensitivity and specificity of quantitative RT-PCR
results for diagnosing occult metastasis were calculated. Patients
classified as having positive or negative quantitative RT-PCR
results according to the classification method were tested for dif-
ferences in disease-free survival with the log-rank test.
Results
Archived Tissue Analysis
Initially we analyzed archived, histologically determine
negative lymph nodes (N0) from 30 patients with
esophageal cancer (Figure 1). Of the 30 tissue blocks ana-
lyzed, 13 had CEA expression higher than the receiver
operating characteristic curve–determined cutoff (>0.183).
Of this group, 9 patients had disease recurrence and had
died by the end of the study, 2 had died of other causes by
the end of the study, and 2 were alive without disease at the
end of the study. Of the remaining 17 patients with negative
quantitative RT-PCR results, 1 had disease recurrence at 5
months and had died by the end of this study, 5 had died of
other causes by the end of the study, and 11 remained alive
and disease free at the end of the study (Table 3). The sen-
sitivity and specificity for predicting disease recurrence of
the rapid quantitative RT-PCR assay were 90% and 80%,
respectively, and 83% of patients in the cohort were classi-
fied correctly. Figure 2 shows the Kaplan-Meier disease-
free survival curves for patients with positive and negative
quantitative RT-PCR results. Survivals at 5 years among
patients with negative and positive quantitative RT-PCR
results were 94% and 20%, respectively. The survival func-
tions for these two groups were statistically significantly
different (P = .001 by log-rank test).
Figure 3. Smart Cycler analysis of CEA expression in frozen lymph nodes. Yellow bars represent nodes from patients
without cancer; blue bars represent nodes determined on final pathologic examination to be negative for disease;
red bars represent nodes found to be positive for disease; striped bars represent nodes that were negative accord-
ing to intraoperative frozen-section analysis but positive according to fixed-tissue histologic examination; red star
represents a highly expressing node from patient with node-negative disease who had recurrence. Samples with no
detectable CEA expression were arbitrarily plotted at 0.001.
480 The Journal of Thoracic and Cardiovascular Surgery • March 2002
General Thoracic Surgery Raja et al
ED
ITO
RIA
L
CH
D
G
TS
G
TS
ET
CSP
TX
According to the proportionate hazards model for dis-
ease-free survival, the relative risk associated with an
increase of 1 unit of CEA expression was 1.52 (95% confi-
dence interval 1.11-2.09, P = .027). That associated with a
CEA expression greater than 0.183 was 3.78 (95% confi-
dence interval 1.34-10.7, P = .0007) relative to CEA expres-
sion of 0.183 or less.
Fresh-Tissue Analysis
Fresh-frozen sections of lymph nodes from patients under-
going minimally invasive staging for esophageal cancer or
benign esophageal disorders were analyzed. In the 11
lymph nodes from the benign cases, rapid quantitative RT-
PCR detected extremely low levels of CEA expression in
only 2 lymph nodes (patients 8 and 11, Figure 3). This low
level in the benign cases presumably represented back-
ground or ectopic CEA expression. The highest level of
CEA expression in any benign node was 34-fold lower than
the lowest-expressing positive node (Figure 3), which had
only a small focus of tumor involvement.
Of the 26 lymph nodes from 12 patients with esophageal
cancer, 12 nodes from 6 patients were ultimately shown to
be positive on final pathologic examination. In 2 of these
nodes from 2 patients, however, results of intraoperative
frozen-section analysis were negative, and N1 status was
determined after the operation. Rapid quantitative RT-PCR
showed CEA expression levels in these 2 nodes to be in the
range of the histologically determined positive nodes
(patients 18 and 19, Figure 3). Among the 6 patients who
had histologically determined node-negative esophageal
cancer, only one had a single node with increased CEA
expression according to rapid quantitative RT-PCR (patient
15, Figure 3). This patient had a clinical recurrence of his
esophageal cancer at a follow-up of 16.5 months.
Analysis of the calibrator samples on each run revealed
that for 13 separate runs the SD of the change in threshold
cycle value was 0.14 cycles (approximately 10% of the SD
for relative expression measurements). In addition, the
quantitative RT-PCR required approximately 25 minutes for
all 40 cycles. With an RNA isolation time of 5 to 7 minutes,
the entire assay took approximately 30 minutes. In our
hands this was an extremely rapid and reproducible assay.
Discussion
In many malignancies, including esophageal cancer, TNM
staging yields the best prognostic information. The absence
of nodal involvement is associated with a more localized
lesion and suggests that a cure may be obtained by surgical
resection alone. Nodal metastases, in contrast, are indica-
tors of tumor spread beyond the site of the primary tumor
and as such necessitate systemic treatment. Although the
role of chemotherapy in esophageal cancer remains contro-
versial, some trials have shown trends indicating the bene-
fit of preoperative chemotherapy.22,23 One advantage of this
approach is that more patients are able to complete the
chemotherapy protocol than would be able do so if they
were to receive treatment after a surgical procedure that car-
ries a high morbidity. In the near future ongoing prospec-
tive, randomized clinical trials should resolve the utility of
preoperative chemotherapy in patients with esophageal can-
cer. With the advent of minimally invasive surgical
approaches to staging, there is a potential for staging before
resection, which allows the offer of preoperative chemo-
therapy when appropriate. The accurate determination of
nodal stage before attempted curative resection therefore
could become extremely important in the decision-making
process for patients with esophageal cancer.
Currently, intraoperative nodal staging is performed by
frozen sectioning and hematoxylin and eosin staining.
Although this methodology has at least a 93% correlation
with the criterion standard of formalin-fixed, hematoxylin
and eosin–stained tissue examination,24 both methods have
significant limitations. Specifically, 30% to 50% of patients
with histologically determined node-negative esophageal
cancer have disease recurrence despite potentially curative
resection. This finding is most likely the result of the
sampling error that is inherent in the conventional method-
ologies and of a lack of sensitivity for detecting micro-
metastases. Single tumor cells or small foci of cells are
easily missed, because only a couple 4-µm sections are
studied, with the vast majority of each node remaining
unexamined. Serial sectioning of lymph nodes can reduce
the sampling error and thus minimize this limitation. For
example, in studies on breast cancer, serial sectioning of
lymph nodes combined with immunohistochemical meth-
ods led to upstaging of an additional 10% to 23% of nodes
that were negative according to routine histopathologic
evaluation.25,26 This method is not routinely used, however,
because of the significant time and labor involved in serial
sectioning of numerous lymph nodes from each case.
In the last decade many studies have used RT-PCR to
detect tumor-related messenger RNA in lymph nodes in
attempts to improve the sensitivity of micrometastasis detec-
tion. Studies on several cancer types have reported that RT-
PCR is a reasonable prognostic indicator,8-10 but despite this
RT-PCR has not made its way into clinical practice. The
main reasons for this are poor specificity (40%-60%),8,9
false-positive results in control nodes from patients without
cancer,7 and the lack of standardized assays for multicenter
trials. In previous work we showed that quantitative RT-PCR
can overcome false-positive results from background or
ectopic gene expression and can increase the specificity for
predicting disease recurrence.13 With the techniques used in
that study, however, the RNA isolation and RT-PCR assay
requires 4 to 6 hours to complete. As a result, this method
can only be used after the operation. Intraoperative quantita-
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tive RT-PCR will work only if it can be performed rapidly
enough to yield a result in a time frame comparable to that
of intraoperative frozen-section analysis (approximately 20-
30 minutes). Along with rapid RNA isolation and reverse
transcription protocols, this requires extremely fast poly-
merase chain reaction ramping times, such as those attain-
able with the Roche Light Cycler or the Cepheid Smart
Cycle. In this study we used the Caught instrument because
of the relative ease of use (no glass capillaries), the indepen-
dent control of each reaction site, the availability of 4-color
multiplexing, and the potential for automated sample prepa-
ration and quantitative RT-PCR. With this instrument we
have shown that a quantitative RT-PCR assay can be per-
formed on OCT-embedded tissue sections within 30 minutes
from RNA extraction to result. With modifications to the
protocol reported here, our current, fastest quantitative RT-
PCR can be carried out in 18.5 minutes (data not shown).
With our rapid assay we performed a retrospective analy-
sis of RNA from archival tissues with a median patient fol-
low-up of 36 months. Our data showed that the rapid assay
predicted disease recurrence with a sensitivity and specificity
of 90% and 80%, respectively. These data were comparable
with the slower, and more traditional, TaqMan-based analy-
sis (90% and 90%). In our fresh-tissue analysis, we were
clearly able to distinguish all the histologically determined
positive nodes from the benign control nodes in less than 30
minutes. On the basis of the expression level of CEA, it was
also possible to characterize pathologically negative nodes as
having an expression pattern that resembled either benign or
pathologically positive nodes. From our data, it appears that
rapid quantitative RT-PCR is at least as sensitive as fixed-tis-
sue examination and is more sensitive than intraoperative
frozen section examination. This is demonstrated by the 2
positive nodes that were deferred or misdiagnosed during the
intraoperative examination. To confirm this data, we are plan-
ning to study a much larger number of fresh lymph nodes and
correlate the results with pathologic staging. As the data set
matures, we will also correlate quantitative RT-PCR with
recurrence. This should allow us to set an optimal CEA
expression cutoff value in the fresh-tissue data set, because it
may be different from the cutoff for archived tissues. Because
of our promising preliminary fresh-tissue data and problems
inherent in analysis of archived tissues, we are hopeful that
specificity and positive predictive values will improve with
analysis of fresh tissues.
We realize that further development of this technology
will be necessary to bring intraoperative quantitative RT-
PCR from bench to bedside. In a clinical setting the quanti-
tative RT-PCR assay has to be a simple and automated
process, with minimal handling. Toward this end our goal is
to develop a cartridge-based processor for automated analy-
sis. We envision that the end product will be a single-use
disposable cartridge capable of both RNA isolation and
quantitative RT-PCR setup. When integrated with a rapidly
cycling, real-time quantitative thermal cycle, this system
will provide a quantitative RT-PCR result from frozen sec-
tions in less than 25 minutes. With the identification of new
and accurate markers, this technology could also be used
for molecular analysis of surgical margins and as an adjunct
to fine-needle aspirate cytologic examination. Thus molec-
ular information regarding micrometastases and complete-
ness of resection could for the first time be made available
to the surgeon during the operation. Furthermore, the avail-
ability of an automated and reproducible quantitative RT-
PCR format would allow the true molecular diagnostic
value of quantitative RT-PCR to be evaluated in standard-
ized multicenter trials.
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Discussion
Dr Jack A. Roth (Houston, Tex). Raja and colleagues are to be
congratulated for this novel and important presentation. I am fre-
quently asked why thoracic surgeons should be familiar with the
molecular biology of cancer. This interesting presentation pro-
vides an answer to that question: molecular diagnostics and thera-
peutics will be increasingly important tools in the management of
patients with thoracic cancers. If we as surgeons are to play a sig-
nificant role in the management of these cases, we need to be on
the cutting edge of this technology.
This presentation describes an important advance in the use of
cancer gene expression for the staging of esophageal cancer. To
use this information clinically, it must be available rapidly, which
is made possible by a technical advance in instrument design.
Realistically, Raja and colleagues were able to show about a 10-
fold difference between lymph nodes with no evidence of metas-
tases and lymph node cells expressing levels of CEA, which is also
expressed at high levels by esophageal cancer cells. This differ-
ence is likely to be clinically useful.
An important issue raised by this study is the biologic behav-
ior and significance of the micrometastases detected by this tech-
nique. Does the expression of a marker such as this really correlate
with the presence of metastatic cancer cells? Dr Raja, are you
planning a larger study to address this?
Some technical points could also be better addressed. CEA is
not a highly tumor-associated protein and may, for example, be
expressed by normal cells from smokers. Raja and colleagues now
have many oncogene and tumor suppressor gene targets from
which to choose. Dr Raja, have you expanded this study to include
other tumor markers?
The number of patients in the study was small, and no indica-
tion of the variability of their triplicate samples is provided. How
reproducible is the assay? Although the 30 minutes reported by the
authors is faster than a frozen-section analysis at our institution,
information showing the actual times needed to perform the assay
would be useful and could convince impatient surgeons that this
assay really can be used in the operating room.
The lower sensitivity of the frozen-section analysis is balanced
by the reduced specificity of the RT-PCR assay, and the overall
accuracies of the two procedures are therefore really similar.
Thus, it is not clear that the additional information gained is cost-
effective. The value of this technique to assess nodal positivity in
the operating room may have limited utility if, as for many tho-
racic cancers, a complete resection can be performed, surgery
would proceed in that instance despite the presence of nodal
metastases. However, this technique might be useful for assessing
surgical margins. Dr Raja, have you used the technique for that
purpose?
Use of this technique with fine-needle aspirate cytologic exam-
ination also might greatly improve staging accuracy. However, I
believe that the real value of this technique is in rapidly establish-
ing the molecular profile of the cancer. Rapid determination of
molecular genetic profiles of the tumor will enable genetic lesions
in cancer, such as overexpression of p53 or epidermal growth fac-
tor or angiogenic factors, to be specifically targeted with induction
therapy. The first restoration of tumor suppressor gene function in
lung cancer was reported 5 years ago, and now this treatment has
been evaluated in many patients and has become a clinical reality.
Genetically targeted therapies will become important adjuncts to
surgery during the next 5 years, and genetic testing will be impor-
tant in determining prognosis and therapy. Raja and colleagues are
to be congratulated for leading us into the future.
Dr Raja. Regarding your first question about larger studies,
since the time of this work we have been collecting tissues to be
able to ultimately look at a much larger population of patients. We
have not reached the accrual limit, and we therefore have not done
the assays on those samples yet, but we are in the process of col-
lecting the samples.
In answer to your second query, CEA was one of many markers
that we had investigated, the others in the context of esophageal
cancer being cytokeratin 19 and Mucin-1. CEA appeared to be the
most sensitive and specific of these markers. Cytokeratin 19 was
detected by immunohistochemical staining in mesothelium by our
group, and because the samples were archived and we had no con-
trol over some of the tissues that were included, we could make
sure that our blocks did not have esophageal tissue or epithelial
cells but could not be certain that mesothelium was not present. We
therefore excluded the other markers in this study. We are expand-
ing our bank of molecular markers and molecular targets, and at the
moment we have not used that in esophageal cancer.
To address your question about reproducibility, our assay is
highly reproducible. We run a calibrator sample (the same RNA
sample) along with every run in every experiment. The SD for this
from run to run, for 13 runs, is 0.14 of the cycle, and the range is
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0.43, which is significantly less than a 2-fold difference. I think
that this reproducibility has been lacking in the traditional stan-
dard RT-PCR, and that it is being addressed by quantitative RT-
PCR is what will ultimately be important in creating a clinical
assay. The actual times to make this entire assay possible in our
hands have been less than 25 minutes, with the RNA extraction
being at 5 to 6 minutes.
In terms of the sensitivity and specificity of pathologic exami-
nation versus RT-PCR, we found that according to our survival
curves this assay was similar to pathologic analysis, because a
subset of patients have N1 disease and still survive. Looking at our
fresh-tissue data, however, there seems to be a much better sepa-
ration between the positive nodes and the negative nodes. So we
believe that this assay, in combination with a multimarker
approach, should resolve any issues of slightly decreased speci-
ficity that we are seeing in our study.
We are currently investigating the potential for verifying surgi-
cal margins. This approach is complicated by the fact that you
need to find specific markers that are present in the tumor but not
in the tissue from which it originated. DNA-based markers may
provide an answer.
To answer the final question about the molecular profiling of
these tumors, our work at the moment is a proof of principle. We
have shown that the assay can be done in a rapid fashion. Once the
assay is developed, modification to include other molecular tar-
gets, both DNA and RNA, should be quick to follow.
Notice from the American Board of Thoracic Surgery
regarding trainees and candidates for certification who are
called to military service related to the war on terrorism
The Board appreciates the concern of those who have received emergency call to military
service. They may be assured that the Board will exercise the same sympathetic considera-
tion as was given to candidates, in recognition of their special contributions to their country,
during the Viet Nam conflict and the Persian Gulf conflict with regard to applications, exami-
nations, and interruption of training. If you have any questions about how this might affect
you, please call the Board office at 847-475-1520.
Peter C. Pairolero, MD
Chair
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